The local medical sector is buzzing with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in clinical trials for addressing obesity. This treatment suggests a https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/